If you have been reading about carcinogenicity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-04. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
== Analysis == The groups of bioactive compounds present in E. planum are phenolic acids, triterpenoid saponins, flavonoids, coumarins, and essential oils. The wide range of compounds is reflected in the wide range of uses. Qualitative and quantitative determinations of the phenolic acids by reverse phase high-performance liquid chromatography (RP HPLC) show relatively small amounts of rosmarinic, chlorogenic, and caffeic acids in the basal leaves and the roots of intact plants, and greater concentrations in E. planum from in vitro cultures. Qualitative and quantitative analyses of the essential oil compounds performed by gas chromatography with a flame ionization detector linked to a mass spectrometer (GC-FID-MS) show the main components of stalk leaf oil, and rosette leaf oil, as monoterpenes (limonene, and α- and β-pinene), sesquiterpenes, and hydrocarbons. (Z)-Falcarinol was found as the major component of root essential oil.
Francisco Rodríguez, an economist, called on Venezuela's National Assembly to reject the deal, describing it as "predatory" and arguing that transferring Venezuelan oil wealth to the United States was unconstitutional and not in the country's interest, particularly when carried out under the threat of force. Gregory Brew, an energy historian and analyst at the Eurasia Group, expressed skepticism about the agreement, predicting significant opposition to any deal that would give the U.S. government effective control over Venezuelan resources. He compared the arrangement to the early 20th-century control exercised by the Anglo-Persian Oil Company over oil resources in Iraq and Iran, and suggested that for Trump, control over oil appeared to be an objective in itself, with the arrangement carrying colonial overtones. On 31 August, The New York Times reported that the arrangement would give the Defense Department the option to acquire up to 35 per cent of the parent company of Betancourt's firm through a warrant, described by two people familiar with the deal as a penny warrant convertible into shares for as little as one cent. The White House said the same day that the partnership came "all at zero cost to the United States", that the federal government would be guaranteed 20 per cent of the company's output at production cost with the State Department holding a right of first refusal over the remainder, and that the United States would hold a veto over appointments to the company's board, a majority of whose members would have to be American citizens.
== Works by Kenyon == Kenyon DH, Steinman G. Biochemical Predestination. McGraw Hill Text (1969) ISBN 0-07-034126-5. Davis PW, Kenyon DH. Of Pandas and People: The Central Question of Biological Origins. Foundation for Thought & Ethics; 2nd edition (1993) ISBN 0-914513-40-0. Steinman, G; Kenyon, DH; Calvin, M (August 1966). "The mechanism and protobiochemical relevance of dicyanamide-medicated peptide synthesis". Biochim. Biophys. Acta. 124: 339–50. PMID 5968904. Smith, AE; Kenyon, DH (1972). "Is life originating de novo?". Perspect. Biol. Med. 15: 529–42. PMID 5040075. Smith, AE; Kenyon, DH (July 1972). "The origin of viruses from cellular genetic material". Enzymologia. 43: 13–8. PMID 5050651. Smith, AE; Kenyon, DH (1973). "A unifying concept of carcinogenesis and its therapeutic implications". Oncology. 27 (5): 459–79. PMID 4578174. Smith, AE; Kenyon, DH (January 1973). "Acupuncture and A.T.P.: how they may be related". Am J Chin Med (Gard City N Y). 1: 91–7. PMID 4774360. Kenyon, DH (July 1975). "On terminology in origin of life studies". Orig. Life. 6: 447–9. PMID 1187108. Nissenbaum, A; Kenyon, DH; Oro, J (December 1975). "On the possible role of organic melanoidin polymers as matrices for prebiotic activity". J. Mol. Evol. 6: 253–70. PMID 1542. Kenyon, DH; Nissenbaum, A (April 1976). "Melanoidin and aldocyanoin microspheres: implications for chemical evolution and early precambrian micropaleontology". J. Mol. Evol. 7: 245–51. PMID 778393.
Sources: en.wikipedia.org
"Chamber acid" and "tower acid" were the two concentrations of sulfuric acid produced by the lead chamber process, chamber acid being the acid produced in the lead chamber itself (<70% to avoid contamination with nitrosylsulfuric acid) and tower acid being the acid recovered from the bottom of the Glover tower. They are no longer used in commercial applications, although they may be prepared in the laboratory from concentrated sulfuric acid if needed. In particular, "10 M" sulfuric acid (the modern equivalent of chamber acid, used in many titrations) is prepared by slowly adding 98% sulfuric acid to an equal volume of water, with good stirring: the temperature of the mixture can rise to 80 °C (176 °F) or higher.
This engagement is widely regarded in South Africa as the start of the Border War, and according to SWAPO, officially marked the beginning of its revolutionary armed struggle. Operation Blouwildebees triggered accusations of treachery within SWALA's senior ranks. According to SADF accounts, an unidentified informant had accompanied the security forces during the attack. Sam Nujoma asserted that one of the eight guerrillas from the second group who were captured in Kavangoland was a South African mole. Suspicion immediately fell on Leonard "Castro" Shuuya. SWALA suffered a second major reversal on 18 May 1967, when Tobias Hainyeko, its commander, was killed by the South African police. Heinyeko and his men had been attempting to cross the Zambezi River, as part of a general survey aimed at opening new lines of communication between the front lines in South West Africa and SWAPO's political leadership in Tanzania. They were intercepted by a South African patrol, and the ensuing firefight left Heinyeko dead and two policemen seriously wounded. Rumours again abounded that Shuuya was responsible, resulting in his dismissal and subsequent imprisonment. In the weeks following the raid on Omugulugwombashe, South Africa detained thirty-seven SWAPO politicians, namely Andimba Toivo ya Toivo, Johnny Otto, Nathaniel Maxuilili, and Jason Mutumbulua. Together with the captured SWALA guerrillas, they were jailed in Pretoria and held there until July 1967. All were charged retroactively under the Terrorism Act.
=== United States === Under the FDA, the process of establishing evidence for vaccine clinical safety and efficacy is the same as for the approval process for prescription drugs. If successful through the stages of clinical development, the vaccine licensing process is followed by a Biologics License Application which must provide a scientific review team (from diverse disciplines, such as physicians, statisticians, microbiologists, chemists) and comprehensive documentation for the vaccine candidate having efficacy and safety throughout its development. Also during this stage, the proposed manufacturing facility is examined by expert reviewers for GMP compliance, and the label must have a compliant description to enable health care providers' definition of vaccine-specific use, including its possible risks, to communicate and deliver the vaccine to the public. After licensure, monitoring of the vaccine and its production, including periodic inspections for GMP compliance, continue as long as the manufacturer retains its license, which may include additional submissions to the FDA of tests for potency, safety, and purity for each vaccine manufacturing step.
Nestlé's factory in Heilongjiang was also implicated: the Taiwanese Department of Health forced the delisting of six Neslac and KLIM products on 2 October for containing minute traces of melamine, although the minister said they did not pose a significant health risk. Since the milk crisis broke, Nestlé says it has sent 20 specialists from Switzerland to five of its Chinese plants to strengthen chemical testing. On 31 October, it announced the opening of a $10.2 million Beijing research and development centre, to "serve as the base and the reference in food safety for Nestlé in Greater China". Nestlé Chief Technology Officer said the centre was equipped with "highly sophisticated analytical tools for detecting trace amounts of residues and undesirable compounds like melamine or veterinary drugs or natural toxins".
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.